Reduced Drug Pricing Within View and More Good Policy News 

At Medicines360, our work is focused on addressing gaps women face in accessing the medicines they need. While that means we pursue drug research and development, as a mission-driven organization, it also demands that we pay attention to and speak up about policies that negatively impact the health and well-being of women we serve. In that spirit, as we move into the second quarter of 2023 and the 118th Congress, we have some key policy updates to share.  

Key Updates

Insulin Gets a Price Cap with Nonprofit Pharma as an Ally

In March, the state of California announced its partnership with fellow nonprofit pharmaceutical company Civica Rx. The $50 million investment will cap the cost of insulin at $30 per vial for Californians, regardless of their insurance status. We applaud Civica’s work to tackle supply chain issues and bring affordable, critical medicines to the people of California and nationwide. This move serves as an important milestone for public partnerships with nonprofit pharma, and we are confident it will pave the way for future partnerships down the road.

The Real-world Impact of Drug Pricing Legislations

We are thrilled to share that the progress does not stop there—nonprofit pharma and smart policy are building a future with more equitable access to critical medicines. In March, pharmaceutical companies Novo Nordisk, Sanofi SA, and Eli Lilly announced drastic cuts to their insulin prices which will help ensure more equitable access to the life-saving drug. These changes were strategic: a provision in the American Rescue Plan Act of 2021 designed to lower Medicaid rebate caps meant that, by lowering their prices, these pharmaceutical companies are actually avoiding paying millions of dollars in rebates to state Medicaid programs starting in 2024.

Ultimately, these price cuts demonstrate the positive, real-world impact that drug pricing legislation can have and the powerful market pressure that nonprofit pharma companies like Civica and Medicines360 can exert. 

Over-the-Counter Health Products in Review

In June of last year, the Food and Drug Administration (FDA) announced a Proposed Rule on Nonprescription Drug Products with an Additional Condition for Nonprescription Use. The proposed rule was designed to increase options for the development and marketing of nonprescription drugs, with the intended effect of improving public health by broadening the types of products available without a prescription.

However, our policy team cautions that the proposed rule’s new conditions could potentially impede access to over-the-counter women’s health products and deepen harmful inequities in access for women from marginalized communities. Additionally, the proposed rule’s new tracking requirements could create unnecessary burdens for patients and for manufacturers—particularly at a time when patient privacy is more important than ever. In response, we submitted comments to the FDA expressing our views. While a final rule has not yet been published, we are hopeful that the FDA will heed these important concerns. 

About Medicines360

Located in San Francisco, California, Medicines360 is a global nonprofit pharmaceutical organization with a mission to accelerate the timeline from health innovation to access for all women. Medicines360 is committed to working with healthcare providers, advocacy groups, and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.